Subscribe To
GKOS / Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
GKOS News
By Seeking Alpha
November 1, 2023
Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Inv more_horizontal
By Zacks Investment Research
November 1, 2023
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal
By Zacks Investment Research
October 5, 2023
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal
By Zacks Investment Research
August 2, 2023
Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compar more_horizontal
By Zacks Investment Research
July 20, 2023
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal
By Zacks Investment Research
July 19, 2023
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detec more_horizontal
By Seeking Alpha
June 16, 2023
Glaukos: Revising To Buy On These 3 Catalytic Factors
Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. more_horizontal
By Zacks Investment Research
May 19, 2023
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal